Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Tafasitamab-Cxix Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tafasitamab-Cxix: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Bempedoic acid/Ezetimibe Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Bempedoic acid/Ezetimibe: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Remimazolam Besylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Remimazolam Besylate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Gallium GA-68 Gozetotide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Gallium GA-68 Gozetotide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
AGPAT5 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGPAT5, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGPAT4 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGPAT4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGPAT3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGPAT3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGPAT2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGPAT2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGPAT1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGPAT1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGO4 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGO4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGO3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGO3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
AGO2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
24 July 2026
A visual target evaluation report for AGO2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.